XML 151 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]        
REAL PROPERTY RENTAL REVENUE $ 349,800 $ 314,588 $ 1,333,403 $ 1,255,681
REAL PROPERTY OPERATING EXPENSES 280,390 263,126 1,065,574 1,017,493
REAL PROPERTY OPERATING INCOME 69,410 51,462 267,829 238,188
INCOME FROM EQUITY METHOD INVESTMENT - LAB SERVICES MSO 392,677 107,469 (846,588) (8,571,647)
OTHER OPERATING EXPENSES:        
Advertising and marketing expenses 71,150 45,000 237,671 1,666,721
Professional fees 1,691,579 442,335 1,822,105 3,076,477
Compensation and related benefits 340,420 353,571 1,431,328 1,768,449
Other general and administrative expenses 165,713 161,087 857,869 908,577
Total Other Operating Expenses 2,268,862 1,001,993 4,348,973 7,420,224
LOSS FROM OPERATIONS (1,806,775) (843,062) (4,927,732) (15,753,683)
OTHER (EXPENSE) INCOME        
Interest expense - amortization of debt discount and debt issuance costs (313,562) (272,196) (1,411,042) (544,010)
Interest expense - other (246,456) (236,215) (983,486) (773,780)
Interest expense - related party   (10,596) (42,445) (33,712)
Debt modification charge     (838,794)
Change in fair value of derivative liability (114,360) 31,212 374,365 188,374
Impairment of equity method investment - Epicon     (454,679)
Gain on debts extinguishment     682,979
Other expense (958) (36,656) (74,260) (18,499)
Total Other Expense, net (675,336) (524,451) (2,975,662) (953,327)
LOSS BEFORE INCOME TAXES (2,482,111) (1,367,513) (7,903,394) (16,707,010)
INCOME TAXES
NET LOSS (2,482,111) (1,367,513) (7,903,394) (16,707,010)
LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST
NET LOSS AFTER NONCONTROLLING INTEREST (2,482,111) (1,367,513) $ (7,903,394) $ (16,707,010)
DEEMED CONTRIBUTION ON EXCHANGE OF EQUITY INSTRUMENTS 162,473    
NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS $ (2,319,638) $ (1,367,513)    
NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS:        
Net Loss Per Common Share Attributable Common Shareholders Basic (in Dollars per share) $ (1.43) $ (1.86) $ (8.44) $ (23.8)
Net Loss Per Common Share Attributable Common Shareholders Diluted (in Dollars per share) $ (1.43) $ (1.86) $ (8.44) $ (23.8)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:        
Weighted Average Common Shares Outstanding Basic (in Shares) 1,624,629 735,225 936,614 701,932
Weighted Average Common Shares Outstanding Diluted (in Shares) 1,624,629 735,225 936,614 701,932
COMPREHENSIVE LOSS:        
NET LOSS $ (2,482,111) $ (1,367,513) $ (7,903,394) $ (16,707,010)
OTHER COMPREHENSIVE LOSS        
Unrealized foreign currency translation gain (loss) 279 (2,920) (273) (18,590)
COMPREHENSIVE LOSS (2,481,832) (1,370,433) (7,903,667) (16,725,600)
LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST
COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS $ (2,481,832) $ (1,370,433) $ (7,903,667) $ (16,725,600)